https://www.fda.gov/regulatory-information/search-fda-guidance-documents/enforcement-policy-remote-digital-pathology-devices-during-coronavirus-disease-2019-covid-19-public?utm_campaign=2020-04-24%20FDA%20Issues%20New%20Policy%20for%20Remote%20Digital%20Pathology%20Devices&utm_medium=email&utm_source=Eloqua

FDA Issues New Policy for Remote Digital Pathology Devices

The U.S Food and Drug Administration (FDA) has issued an immediately in effect guidance to help expand the availability of devices for remote reviewing and reporting of scanned digital images of pathology slides (“digital pathology slides”) during this pandemic.

Read the Guidance

Increased availability of these devices may help to facilitate continuity of patient care by preventing disruptions to critical pathology services rendered by clinical laboratories, hospitals, and other health care facilities, and by reducing health care personnel contact and risk of exposure to SARS-CoV-2. Questions? If you have questions about this guidance, send email to CDRH-COVID19-DigitalPathology@fda.hhs.gov.